Correspondence 0001493152-23-005837 from OKYO Pharma Ltd (OKYO) (CIK 0001849296) (OKYO)
OKYO Pharma Ltd (OKYO) (CIK 0001849296)
Date: Feb. 23, 2023 · CIK: 0001849296 · Accession: 0001493152-23-005837
AI Filing Summary & Sentiment
File numbers found in text: 333-268675
Letter
Re: OKYO Pharma Ltd.
Aegis Capital Corp.
February 23, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F. Street, N.E.
Washington, DC 20549
Registration Statement on Form F-1/A
File No. 333-268675
Concurrence in Acceleration Request
Ladies and Gentlemen:
Aegis Capital Corp. (“Aegis”), as placement agent for the referenced offering, hereby concurs in the request by OKYO Pharma Ltd. that the effective date of the above-referenced registration statement be accelerated to 5:00 pm (Eastern Time), or as soon as practicable thereafter, on February 27, 2023, pursuant to Rule 461 under the Securities Act. Aegis affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Aegis Capital Corp.
By: /s/ Griffin Cassagne
Name: Griffin Cassagne
Title: Executive Vice President
Show Raw Text
CORRESP
1
filename1.htm
Aegis Capital Corp.
February
23, 2023
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F. Street, N.E.
Washington,
DC 20549
Re:
OKYO Pharma Ltd.
Registration
Statement on Form F-1/A
File
No. 333-268675
Concurrence
in Acceleration Request
Ladies
and Gentlemen:
Aegis
Capital Corp. (“Aegis”), as placement agent for the referenced offering, hereby concurs in the request by OKYO
Pharma Ltd. that the effective date of the above-referenced registration statement be accelerated to 5:00 pm (Eastern Time), or as soon
as practicable thereafter, on February 27, 2023, pursuant to Rule 461 under the Securities Act. Aegis affirms that it is aware
of its obligations under the Securities Act in connection with this offering.
Aegis
Capital Corp.
By:
/s/
Griffin Cassagne
Name:
Griffin
Cassagne
Title:
Executive
Vice President